ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

ASSESSMENT OF EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE TREATMENT FOR PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY USING THE EQ-5D 5L QUALITY OF LIFE QUESTIONNAIRE

Journal: Art of Medicine (Vol.6, No. 3)

Publication Date:

Authors : ;

Page : 28-35

Keywords : chemotherapy; peripheral neuropathy; EQ-5D quality of life questionnaire; alpha-lipoic acid; acetylcholinesterase inhibitors;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Introduction. Paclitaxel is the most common chemotherapeutic agent fromthe taxane family, which is effective in treating many cancer types, including breast cancer. Despite the benefits of taxane-containing treatment regimens, patients develop neurosensory and neuromotor symptoms associated with the treatment, a condition known as chemotherapy-induced peripheral neuropathy.The aim of the study. To evaluate the efficacy of a combination of alpha-lipoic acid and acetylcholinesterase inhibitor ipidacrine hydrochloride to prevent the development of paclitaxel-induced peripheral neuropathy and improveits course in patients with breast cancer using the data ofthe EQ-5D 5LQuality of Life Questionnaire.Materials and methods.The study was conducted on 70 patients with breast cancer (T1-4N0-3M0-1),who were hospitalized at the Precarpathian Clinical Oncology Center of Ivano-Frankivsk Regional Council in 2014-2022. All patients received six cycles of chemotherapy according to the AT or ET regimens: paclitaxel at a dose of 175 mg/m2asa 3-hour infusion + doxorubicin 60 mg/m2(AT), or paclitaxel at a similar dose + epirubicin 90 mg/m2(ET) oncein 3 weeks in neoadjuvant, adjuvant or palliative modes. Patients were randomized into two groups: patients of group I (n = 35) received polychemotherapy without the use of drugs for the prevention of neuropathy,and patientsof group II (n = 35) received polychemotherapy and apreventive treatmentof neuropathy. The scheme for the prevention of paclitaxel-induced peripheral neuropathy included a combination of alpha-lipoic acid with an acetylcholinesterase inhibitor ipidacrine hydrochloride.In order to assess the quality of life and effectiveness of the studied paclitaxel-induced peripheral neuropathy prevention regimen in patients with breast cancer, we have usedthe EQ-5D 5L quality of life questionnaire beforeandafter the 3rd and 6th cycles of paclitaxel chemotherapy.Results.Thestudy of breast cancer patients showed a statistically significant deterioration in all five aspects of quality of life included in the EQ-5D 5L quality of life questionnaire, which progressed with increasing cumulative dose of paclitaxel. In addition, the application of the study scheme for the prevention of paclitaxel-induced peripheral neuropathy in patients of group II, in contrast to patients of group I, led to a statistically significant improvement according to theiranswers to questions about pain or discomfort, both after 3 and after 6 cycles of chemotherapy with paclitaxel -by 14.09% (p <0.05) and 19.49% (p <0.01), respectively. Accordingtothequestionnaire data, after 6 cycles of chemotherapy self-care ofpatients of group II in contrast to patients of group I significantly improved (by 21.21%, p < 0.05).Patients' answers to questions about the other three aspects of quality of life (mobility, normal daily activities, anxiety or depression) did not show a significant improvement in patients ofgroup II, both after 3 and 6 cycles of paclitaxel chemotherapy. The mean value of the assessment of the general condition according to the visual-analog scale significantly improved after 3 and 6 cycles of chemotherapy with paclitaxel inpatients ofgroup II, in contrast to patients of group I-by 6.80%(p <0.001) and 13.40% (p <0.001), respectively.

Last modified: 2022-11-09 04:54:04